Advertisement
Canada markets open in 8 hours 22 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7304
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    82.95
    +0.14 (+0.17%)
     

  • Bitcoin CAD

    87,915.77
    -3,877.41 (-4.22%)
     

  • CMC Crypto 200

    1,390.19
    -33.91 (-2.38%)
     

  • GOLD FUTURES

    2,326.90
    -11.50 (-0.49%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,453.25
    -211.25 (-1.20%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,676.59
    -783.49 (-2.04%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

What Analysts Recommend for Ionis after Q2 2018

Mike Benson
Updated
What Analysts Recommend for Ionis after Q2 2018

Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.

Continue reading